Business
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathyBLA granted priority review with a Prescription Drug User Fee Act (PDUFA) target action date set for August 31, 2025 Reported positive data from HOPE-2 open label extension (OLE) trial at 2025 MDA Conference showing preservation of skeletal muscle function over 3 years resulting in 52% slowing of disease Received $10
About this update from Capricor Therapeutics, Inc.
[{"type":"image","alt":"Capricor Therapeutics","displaySize":"","headline":null,"caption":"Capricor Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YaI1GjtfVRH2kLVsjMQa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7","width":300,"height":107}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"BLA granted priority review with a Prescription Drug User Fee Act (PDUFA) target action date set for August 31, 2025 ","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported positive data from HOPE-2 open label extension (OLE) trial at 2025 MDA Conference showing preservation of skeletal muscle function over 3 years resulting in 52% slowing of disease ","length":188,"tagName":"p"}]},{"val":[{"type":"text","content":"Received $10 million milestone payment from Nippon Shinyaku; cash balance of approximately $152 million at year-end 2024 expected to support current planned operations into 2027","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"Capricor to host conference call and webcast today at 4:30 p.m. ET","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":728,"olType":false},{"type":"text","content":"SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a corporate update.","length":337,"tagName":"p"},{"type":"text","content":"“2024 was a transformational year for Capricor and the patients we serve as we move closer to our goal of bringing the first cellular therapy to market for the treatment of Duchenne-cardiomyopathy, a condition for which there are no approved therapies" said Linda Marbán, Ph.D., Chief Execu...